Retinitis Pigmentosa Clinical Presentation
- Author: David G Telander, MD, PhD; Chief Editor: Hampton Roy, Sr, MD more...
Presenting symptoms of RP vary, but the classic symptoms are discussed below.
The earliest symptom in RP is most commonly night blindness and is considered a hallmark of the disease.
Patients might report difficulties with tasks at night or in dark places, such as trouble walking in dim lit rooms (eg, movie theaters). Patients may report difficulties driving in low light, at dusk, or in foggy conditions.
Patients may also report a prolonged period of time needed to adapt from light to dark.
Peripheral vision loss is often asymptomatic; however, some patients notice this vision loss and report it as tunnel vision.
Patients may report bumping into furniture or doorframes or difficulties with sports requiring peripheral vision (eg, tennis, basketball).
The loss of vision is painless and slow to progress.
Many patients with RP report seeing flashes of light (photopsia) and describe them as small, shimmering, blinking lights similar to the symptoms of an ophthalmic migraine. However, in contrast to the patient with an ophthalmic migraine, the photopsia may be continuous rather than episodic.
Other history considerations
A careful family history with pedigree and possible examination of family members can be useful.
Drug history is essential to rule out phenothiazine/thioridazine toxicity.
Because RP is a collection of many inherited diseases, significant variability exists in the physical findings. Interestingly, even patients with the same genetic defect can have different clinical manifestations of the disease. The most common findings are described below.
Snelling visual acuity can vary from 20/20 to light perception, but it is usually preserved until late in the disease.
Pupil reaction can be normal with or without afferent pupillary defect.
Patients can develop posterior subcapsular cataracts; up to 50% of adult patients with RP develop this type of cataract.
The retina can appear unaffected early in the disease. Typical key findings include the following:
Bone spicules - Midperipheral retinal hyperpigmentation in a characteristic pattern
Optic nerve waxy pallor
Atrophy of the RPE in the mid periphery of the retina
Retinal arteriolar attenuation
The presence of vitreous cells is common. Patients can have a loss of the foveolar reflex or an abnormal vitreoretinal interface. A subset of patients with RP develops cystoid macular edema with an associated more rapid and potentially reversible loss of vision.
Retinitis punctata albescens, a variant of RP, presents with yellow deposits deep in the retina rather the normal increased pigmentation of the peripheral retina.
Cone-rod retinal degenerations present with central macular pigmentary changes (bull's eye maculopathy). Choroideremia and gyrate atrophy typically present with large scalloped areas of peripheral retinal atrophy.
A physical examination can be helpful to rule out syndromic RP, which are conditions that have pigmentary retinopathy and mimic RP. There are many syndromes; the more common and severe types are described below.
Usher syndrome is a form of RP with hearing loss. As many as 10% of patients with RP can have hearing loss, and most of these patients have Usher syndrome. Hearing loss in this syndrome can be congenital with complete hearing loss or can occur in middle age with less profound changes in hearing. Most cases of Usher syndrome are autosomal recessive, and mutations have been found in more than 12 genetic loci and 8 identified genes.
RP and hearing loss are also associated with Waardenburg syndrome, Alport syndrome, and Refsum disease, all of which have their own systemic manifestations.
Kearns-Sayre syndrome consists of external ophthalmoplegia, lid ptosis, heart block, and pigmentary retinopathy. This syndrome is caused by a mitochondrial genetic defect, and vision loss tends to occur later in life with moderate visual field loss and night vision difficulties. The cardiac conduction block can be life-threatening; therefore, an electrocardiogram (ECG) is essential to help rule out this syndrome in patients.
Abetalipoproteinemia is a condition caused by the lack of apolipoprotein B, leading to fat malabsorption, fat-soluble vitamin deficiencies, spinocerebellar degeneration, and pigmentary retinal degeneration. High-dose therapy with vitamins A and E can prevent or limit the extent of the retinal degeneration.
The mucopolysaccharidoses (eg, Hurler syndrome, Scheie syndrome, Sanfilippo syndrome) can be affected with pigmentary retinopathy like RP.
Bardet-Biedl syndrome consists of polydactyly, truncal obesity, kidney dysfunction, short stature, and pigmentary retinopathy. In this autosomal recessive condition, intelligence is usually subnormal, and vision loss occurs in the second decade and progresses to severe vision loss by middle age. Renal dysfunction can be severe and life-threatening, requiring full evaluation with initial diagnosis.
Neuronal ceroid lipofuscinosis is characterized by dementia, seizures, and pigmentary retinopathy. Progressive vision loss occurs in early-onset cases. These disorders have been categorized clinically in relation to the age of onset and the temporal relation of vision loss to neurologic symptoms.
Onset of the infantile form is at age 8-18 months. The infantile disease is characterized by optic atrophy, macular pigmentary changes with mottling of the periphery, and low or absent electrophysiologic findings (electroretinogram [ERG] and visual-evoked response [VER]). In the infantile forms, the retinal changes can lead to confusion with Leber congenital amaurosis.
Onset of the late infantile form (Jansky-Bielschowsky disease) is age 2-4 years, and onset of the juvenile form (Vogt-Spielmeyer-Batten disease) is age 4-8 years. These forms more prominently show macular granularity or bull's eye maculopathy, and the appearance can be mistaken for a primary retinal dystrophy, such as Stargardt disease.
The adult form is known as Kufs syndrome. This form often does not have ophthalmologic manifestations, but electrophysiologic changes that are indicative of inner retinal and RPE damage have been observed.
RP is a collection of many different genetic diseases that lead to progressive photoreceptor loss and associated vision loss; therefore, the etiology is remarkably variable. As discussed in Pathophysiology, the final common pathway of all these diseases is photoreceptor cell death (predominantly rod photoreceptors). Research has shown that photoreceptor death can be induced by different pathways.
There have been so many important contributions by so many groups around the world that even cataloging them is a formidable task. Fortunately, the authors can refer the reader to the online version of McKusick's classic Mendelian Inheritance of Man (OMIM). Dr. Stephen Daiger also maintains a superb up-to-date Web site called RetNet that is dedicated to the molecular genetics of inherited retinal diseases. As shown on these Web sites, over 196 different genes have been found that lead to retinal disease and vision loss.
This article will not discuss all the genetic defects; however, some of the main defects, including several examples of how characteristic protein defects lead to vision loss and photoreceptor death, are discussed below.
In the United States, about 30% of autosomal dominant RP cases are caused by a mutation of the gene for rhodopsin, and approximately 15% of these cases are from a single point mutation. This single amino acid alteration in the protein rhodopsin then leads to photoreceptor cell death.
The autosomal dominant form of RP (ADRP) is usually the mildest form of RP with later age of onset. ADRP can be caused by mutations in at least 12 different genes, whereas the autosomal recessive form of RP can be triggered by changes in more than 22 different genes. X-linked RP tends to present early and is caused by mutations in only 2 known genes, with 75% of cases caused by a mutation of the retinitis pigmentosa GTPase regulator (RPGR) gene.
Hebrard et al studied autosomal recessive RP by combining gene mapping and phenotype assessment in small, nonconsanguineous families. Comparing whole-genome scans using single nucleotide polymorphisms (SNP) microchips on 2 unrelated sibships with arRP, the study found one candidate gene for each family, thereby determining that only 2 affected individuals in each sibship were sufficient to lead to mutation identification; this can serve to avoid the long process of systematic sequencing of 506 exons.
Photoreceptors are sensitive to light and have been placed in a high oxygen environment. As such, they are sensitive to genetic changes in multiple pathways, which can lead to their demise.
For example, some mutations in genes that control phototransduction and vitamin A delivery are expressed in the RPE (eg, RPE65, RBP, RDH5), but these RPE mutations cause the photoreceptors to die as bystanders, while the RPE initially stays healthy. Alternatively, mutations of the rhodopsin gene are expressed in the photoreceptor itself, which then leads directly to its own death.
Another interesting example is the mutation of the ABCA4 gene, which can cause both RP and Stargardt disease. This mutation affects a membrane protein called a flippase, which is found in the photoreceptor outer segments, and, as it moves, phototransduction molecules (eg, all-trans retinaldehyde) throughout the membrane. Defects in this protein cause a buildup of a toxic molecule that the RPE cells ingest when they phagocytosize the photoreceptor's outer segment. This leads to the death of the RPE. Since the photoreceptor requires the RPE for survival, it then in turn dies as well.
Another major class of mutations in RP affects the RDS/peripherin gene, which is found on chromosome arm 6p. Mutations in this gene also are found in pseudo-RP diseases, such as Gass adult foveal macular dystrophy, pattern dystrophy, and Stargardt-like disease. Therefore, classifying pigmentary retinopathies and dystrophies of the RPE by clinical appearance is problematic.
Mutations in beta-phosphodiesterase, an important protein in the phototransduction cascade, also have been linked to some cases of autosomal recessive RP. Many animal models of RP in dogs and mice demonstrate these and other defects. Underscoring the dichotomy between clinical presentation and genetic defect, a beta-phosphodiesterase mutation also has been linked to a congenital stationary night blindness.
Each syndromic form of RP has genetic defects that lead to photoreceptor death in addition to systemic complications. Over 45 genes have been found to cause these syndromic conditions, including 9 that cause Usher syndrome.
US Food and Drug Administration. FDA approves first retinal implant for adults with rare genetic eye disease [news release]. February 14, 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm339824.htm. Accessed: February 27, 2013.
Saihan Z, Webster AR, Luxon L, Bitner-Glindzicz M. Update on Usher syndrome. Curr Opin Neurol. 2009 Feb. 22(1):19-27. [Medline].
Cottet S, Schorderet DF. Mechanisms of apoptosis in retinitis pigmentosa. Curr Mol Med. 2009 Apr. 9(3):375-83. [Medline].
Grover S, Fishman GA, Anderson RJ, et al. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology. 1999 Sep. 106(9):1780-5. [Medline].
Fahim AT, Bowne SJ, Sullivan LS, et al. Allelic Heterogeneity and Genetic Modifier Loci Contribute to Clinical Variation in Males with X-Linked Retinitis Pigmentosa Due to RPGR Mutations. PLoS One. 2011. 6(8):e23021. [Medline].
Hebrard M, Manes G, Bocquet B, et al. Combining gene mapping and phenotype assessment for fast mutation finding in non-consanguineous autosomal recessive retinitis pigmentosa families. Eur J Hum Genet. 2011 Dec. 19(12):1256-63. [Medline].
Fishman GA, Gilbert LD, Fiscella RG, Kimura AE, Jampol LM. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol. 1989 Oct. 107(10):1445-52. [Medline].
Bastek JV, Heckenlively JR, Straatsma BR. Cataract surgery in retinitis pigmentosa patients. Ophthalmology. 1982 Aug. 89(8):880-4. [Medline].
Neurotech. Results from Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors. Neurotech. Available at http://www.neurotechusa.com/news_events/pr_2009-05-28.asp. Accessed: May 28, 2009.
Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2014 Oct 15. [Medline].
Tsai D, Morley JW, Suaning GJ, Lovell NH. A wearable real-time image processor for a vision prosthesis. Comput Methods Programs Biomed. 2009 Sep. 95(3):258-69. [Medline].
Humayun MS, Weiland JD, Fujii GY, et al. Visual perception in a blind subject with a chronic microelectronic retinal prosthesis. Vision Res. 2003 Nov. 43(24):2573-81. [Medline].
Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Sahel JA, Stanga PE. Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology. 2012 Apr. 119(4):779-88. [Medline].
da Cruz L, Coley BF, Dorn J, Merlini F, Filley E, Christopher P. The Argus II epiretinal prosthesis system allows letter and word reading and long-term function in patients with profound vision loss. Br J Ophthalmol. 2013 May. 97(5):632-6. [Medline].
Chow AY, Pardue MT, Perlman JI, et al. Subretinal implantation of semiconductor-based photodiodes: durability of novel implant designs. J Rehabil Res Dev. 2002 May-Jun. 39(3):313-21. [Medline].
Smith AJ, Bainbridge JW, Ali RR. Prospects for retinal gene replacement therapy. Trends Genet. 2009 Apr. 25(4):156-65. [Medline].
Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years. Arch Ophthalmol. 2012 Jan. 130(1):9-24. [Medline].
Berson EL, Rosner B, Sandberg MA, Weigel-Difranco C, Willett WC. Omega-3 Intake and Visual Acuity in Patients With Retinitis Pigmentosa Receiving Vitamin A. Arch Ophthalmol. 2012 Feb 13. [Medline].
Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther. 2005 Dec. 12(6):1072-82. [Medline].
Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet. 2001 May. 28(1):92-5. [Medline].
Aleman TS, Duncan JL, Bieber ML, et al. Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. Invest Ophthalmol Vis Sci. 2001 Jul. 42(8):1873-81. [Medline].
Amado RG, Chen IS. Lentiviral vectors--the promise of gene therapy within reach?. Science. 1999 Jul 30. 285(5428):674-6. [Medline].
Balciuniene J, Johansson K, Sandgren O, Wachtmeister L, Holmgren G, Forsman K. A gene for autosomal dominant progressive cone dystrophy (CORD5) maps to chromosome 17p12-p13. Genomics. 1995 Nov 20. 30(2):281-6. [Medline].
Bateman JB, Philippart M. Ocular features of the Hagberg-Santavuori syndrome. Am J Ophthalmol. 1986 Aug 15. 102(2):262-71. [Medline].
Baumgartner WA. Etiology, pathogenesis, and experimental treatment of retinitis pigmentosa. Med Hypotheses. 2000 May. 54(5):814-24. [Medline].
Bemelmans AP, Kostic C, Crippa SV, et al. Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis. PLoS Med. 2006 Oct. 3(10):e347. [Medline].
Bennett J. Gene therapy for retinitis pigmentosa. Curr Opin Mol Ther. 2000 Aug. 2(4):420-5. [Medline].
Bennett J, Zeng Y, Bajwa R, Klatt L, Li Y, Maguire AM. Adenovirus-mediated delivery of rhodopsin-promoted bcl-2 results in a delay in photoreceptor cell death in the rd/rd mouse. Gene Ther. 1998 Sep. 5(9):1156-64. [Medline].
Berson EL. Hereditary retinal diseases. Albert DM, Jakobiec FA. Principles and Practices of Ophthalmology. Philadelphia: WB Saunders; 1994. 1181-1262.
Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993 Jun. 111(6):761-72. [Medline].
Berson EL, Rosner B, Sandberg MA, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol. 2004 Sep. 122(9):1306-14. [Medline].
Berson EL, Rosner B, Sandberg MA, et al. Vitamin A supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993 Nov. 111(11):1456-9. [Medline].
Bok D. Ciliary neurotrophic factor therapy for inherited retinal diseases: pros and cons. Retina. 2005 Dec. 25(8 Suppl):S27-S28. [Medline].
Brod RD, Packer AJ, Van Dyk HJ. Diagnosis of neuronal ceroid lipofuscinosis by ultrastructural examination of peripheral blood lymphocytes. Arch Ophthalmol. 1987 Oct. 105(10):1388-93. [Medline].
Chow AY, Chow VY, Packo KH, Pollack JS, Peyman GA, Schuchard R. The artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa. Arch Ophthalmol. 2004 Apr. 122(4):460-9. [Medline].
Cogan DG, Rodrigues M, Chu FC, Schaefer EJ. Ocular abnormalities in abetalipoproteinemia. A clinicopathologic correlation. Ophthalmology. 1984 Aug. 91(8):991-8. [Medline].
Dagnelie G, Zorge IS, McDonald TM. Lutein improves visual function in some patients with retinal degeneration: a pilot study via the Internet. Optometry. 2000 Mar. 71(3):147-64. [Medline].
Dawson WW, Armstrong D, Greer M, Maida TM, Samuelson DA. Disease-specific electrophysiological findings in adult ceroid-lipofuscinosis (Kufs disease). Doc Ophthalmol. 1985 Aug 30. 60(2):163-71. [Medline].
Delyfer MN, Leveillard T, Mohand-Said S, Hicks D, Picaud S, Sahel JA. Inherited retinal degenerations: therapeutic prospects. Biol Cell. 2004 May. 96(4):261-9. [Medline].
Denman S, Weleber R, Hanifin JM, Cunningham W, Phipps R. Abnormal night vision and altered dark adaptometry in patients treated with isotretinoin for acne. J Am Acad Dermatol. 1986 Apr. 14(4):692-3. [Medline].
Doonan F, Cotter TG. Apoptosis: a potential therapeutic target for retinal degenerations. Curr Neurovasc Res. 2004 Jan. 1(1):41-53. [Medline].
Dyer DS, Wilson ME, Small KW, Pai GS. Alström syndrome: a case misdiagnosed as Bardet-Biedl syndrome. J Pediatr Ophthalmol Strabismus. 1994 Jul-Aug. 31(4):272-4. [Medline].
Eiberg H, Gardiner RM, Mohr J. Batten disease (Spielmeyer-Sjøgren disease) and haptoglobins (HP): indication of linkage and assignment to chr. 16. Clin Genet. 1989 Oct. 36(4):217-8. [Medline].
Fain GL. Why photoreceptors die (and why they don't). Bioessays. 2006 Apr. 28(4):344-54. [Medline].
Fan BJ, Tam PO, Choy KW, Wang DY, Lam DS, Pang CP. Molecular diagnostics of genetic eye diseases. Clin Biochem. 2006 Mar. 39(3):231-9. [Medline].
Fishman GA, Farber MD, Derlacki DJ. X-linked retinitis pigmentosa. Profile of clinical findings. Arch Ophthalmol. 1988 Mar. 106(3):369-75. [Medline].
Fishman GA, Gilbert LD, Anderson RJ, Marmor MF, Weleber RG, Viana MA. Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa. Ophthalmology. 1994 Apr. 101(4):687-93. [Medline].
Fishman GA, Kumar A, Joseph ME, Torok N, Anderson RJ. Usher's syndrome. Ophthalmic and neuro-otologic findings suggesting genetic heterogeneity. Arch Ophthalmol. 1983 Sep. 101(9):1367-74. [Medline].
Fleischhauer J, Njoh WA, Niemeyer G. Syndromic retinitis pigmentosa: ERG and phenotypic changes. Klin Monatsbl Augenheilkd. 2005 Mar. 222(3):186-90. [Medline].
Folz SJ, Trobe JD. The peroxisome and the eye. Surv Ophthalmol. 1991 Mar-Apr. 35(5):353-68. [Medline].
Frasson M, Sahel JA, Fabre M, Simonutti M, Dreyfus H, Picaud S. Retinitis pigmentosa: rod photoreceptor rescue by a calcium-channel blocker in the rd mouse. Nat Med. 1999 Oct. 5(10):1183-7. [Medline].
Gal A, Xu S, Piczenik Y, et al. Gene for autosomal dominant congenital stationary night blindness maps to the same region as the gene for the beta-subunit of the rod photoreceptor cGMP phosphodiesterase (PDEB) in chromosome 4p16.3. Hum Mol Genet. 1994 Feb. 3(2):323-5. [Medline].
Gouras P, Carr RE. Electrophysiological studies in early retinitis pigmentosa. Arch Ophthalmol. 1964 Jul. 72:104-10. [Medline].
Grant CA, Berson EL. Treatable forms of retinitis pigmentosa associated with systemic neurological disorders. Int Ophthalmol Clin. 2001 Winter. 41(1):103-10. [Medline].
Heckenlively J. The frequency of posterior subcapsular cataract in the hereditary retinal degenerations. Am J Ophthalmol. 1982 Jun. 93(6):733-8. [Medline].
Heckenlively JR. Retinitis Pigmentosa. XIV. Philadelphia: Lippincott; 1988.
Herse P. Retinitis pigmentosa: visual function and multidisciplinary management. Clin Exp Optom. 2005 Sep. 88(5):335-50. [Medline].
Hims MM, Diager SP, Inglehearn CF. Retinitis pigmentosa: genes, proteins and prospects. Dev Ophthalmol. 2003. 37:109-25. [Medline].
Hollyfield JG, Anderson RE, LaVail MM. Retinal Degenerative Diseases and Experimental Therapy. XIV.  leaf of col. plates. New York: Kluwer Academic/Plenum Publishers; 1999.
Hunter DG, Fishman GA, Mehta RS, Kretzer FL. Abnormal sperm and photoreceptor axonemes in Usher's syndrome. Arch Ophthalmol. 1986 Mar. 104(3):385-9. [Medline].
Joshi AR, Mullen L, Small KW. The retina: genetic studies of several retinopathies located on the short arm of chromosome 17. Curr Opin Neurol. 1997 Feb. 10(1):31-5. [Medline].
Kalloniatis M, Fletcher EL. Retinitis pigmentosa: understanding the clinical presentation, mechanisms and treatment options. Clin Exp Optom. 2004 Mar. 87(2):65-80. [Medline].
Kaplan J, Gerber S, Bonneau D, et al. A gene for Usher syndrome type I (USH1A) maps to chromosome 14q. Genomics. 1992 Dec. 14(4):979-87. [Medline].
Kennan A, Aherne A, Humphries P. Light in retinitis pigmentosa. Trends Genet. 2005 Feb. 21(2):103-10. [Medline].
Kimberling WJ, Moller CG, Davenport S, et al. Linkage of Usher syndrome type I gene (USH1B) to the long arm of chromosome 11. Genomics. 1992 Dec. 14(4):988-94. [Medline].
Kimberling WJ, Moller CG, Davenport S, et al. Lutein and zeaxanthin exhibit photoprotective and anti-apoptotic activities in vitro. Invest Ophthalmol Vis Sci. 1998.
Kimberling WJ, Weston M, Moller C. Clinical and genetic heterogeneity of Usher syndrome. Wright AF, Jay B. Molecular Genetics of Inherited Eye Disorders. Chur, Switzerland: Harwood; 1994. 359-382.
Kimura AE, Drack AV, Stone EM. Retinitis pigmentosa and associated disorders. Wright K, ed. Pediatric Ophthalmology and Strabismus. St. Louis: Mosby; In press.
Marmor MF. The electroretinogram in retinitis pigmentosa. Arch Ophthalmol. 1979 Jul. 97(7):1300-4. [Medline].
Marmor MF, Kessler R. Sildenafil (Viagra) and ophthalmology. Surv Ophthalmol. 1999 Sep-Oct. 44(2):153-62. [Medline].
Masuno M, Shimozawa N, Suzuki Y, et al. Assignment of the human peroxisome assembly factor-1 gene (PXMP3) responsible for Zellweger syndrome to chromosome 8q21.1 by fluorescence in situ hybridization. Genomics. 1994 Mar 1. 20(1):141-2. [Medline].
McLaughlin ME, Sandberg MA, Berson EL, Dryja TP. Recessive mutations in the gene encoding the beta-subunit of rod phosphodiesterase in patients with retinitis pigmentosa. Nat Genet. 1993 Jun. 4(2):130-4. [Medline].
Miggiano GA, Falsini B. [Diet and management of degenerative diseases of the retina (retinitis pigmentosa)]. Clin Ter. 2004 Jul-Aug. 155(7-8):347-51. [Medline].
Moosajee M. Genes and the eye. J R Soc Med. 2005 May. 98(5):206-7. [Medline].
Moraes CT, DiMauro S, Zeviani M, et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med. 1989 May 18. 320(20):1293-9. [Medline].
Murakami A, Yajima T, Inana G. Isolation of human retinal genes: recoverin cDNA and gene. Biochem Biophys Res Commun. 1992 Aug 31. 187(1):234-44. [Medline].
Naash ML, Peachey NS, Li ZY, et al. Light-induced acceleration of photoreceptor degeneration in transgenic mice expressing mutant rhodopsin. Invest Ophthalmol Vis Sci. 1996 Apr. 37(5):775-82. [Medline].
Nadig MN. Development of a silicon retinal implant: cortical evoked potentials following focal stimulation of the rabbit retina with light and electricity. Clin Neurophysiol. 1999 Sep. 110(9):1545-53. [Medline].
Naka H, et al. Ascorbic acid does not protect photic injury by blue light in the rat retina. Invest Ophthalmol Vis Sci. 1998.
Newsome DA. Retinal fluorescein leakage in retinitis pigmentosa. Am J Ophthalmol. 1986 Mar 15. 101(3):354-60. [Medline].
Norton EW. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993 Nov. 111(11):1460; author reply 1463-5. [Medline].
Paskowitz DM, LaVail MM, Duncan JL. Light and inherited retinal degeneration. Br J Ophthalmol. 2006 Aug. 90(8):1060-6. [Medline].
Petersen-Jones S. Advances in the molecular understanding of canine retinal diseases. J Small Anim Pract. 2005 Aug. 46(8):371-80. [Medline].
Phelan JK, Bok D. A brief review of retinitis pigmentosa and the identified retinitis pigmentosa genes. Mol Vis. 2000 Jul 8. 6:116-24. [Medline].
Pilli S, Zawadzki RJ, Telander DG. The dose-dependent macular thickness changes assessed by fd-oct in patients with retinitis pigmentosa treated with ciliary neurotrophic factor. Retina. 2014 Jul. 34(7):1384-90. [Medline].
Polak BC, Hogewind BL. Macular lesions in Alport's disease. Am J Ophthalmol. 1977 Oct. 84(4):532-5. [Medline].
Radtke ND, Aramant RB, Seiler M, Petry HM. Preliminary report: indications of improved visual function after retinal sheet transplantation in retinitis pigmentosa patients. Am J Ophthalmol. 1999 Sep. 128(3):384-7. [Medline].
Radtke ND, Aramant RB, Seiler MJ, Petry HM, Pidwell D. Vision change after sheet transplant of fetal retina with retinal pigment epithelium to a patient with retinitis pigmentosa. Arch Ophthalmol. 2004 Aug. 122(8):1159-65. [Medline].
Radtke ND, Seiler MJ, Aramant RB, Petry HM, Pidwell DJ. Transplantation of intact sheets of fetal neural retina with its retinal pigment epithelium in retinitis pigmentosa patients. Am J Ophthalmol. 2002 Apr. 133(4):544-50. [Medline].
Rivolta C, Sharon D, DeAngelis MM, Dryja TP. Retinitis pigmentosa and allied diseases: numerous diseases, genes, and inheritance patterns. Hum Mol Genet. 2002 May 15. 11(10):1219-27. [Medline].
Rosenfeld PJ, Cowley GS, McGee TL, Sandberg MA, Berson EL, Dryja TP. A null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and autosomal recessive retinitis pigmentosa. Nat Genet. 1992 Jun. 1(3):209-13. [Medline].
Sankila EM, Pakarinen L, Kaariainen H, et al. Assignment of an Usher syndrome type III (USH3) gene to chromosome 3q. Hum Mol Genet. 1995 Jan. 4(1):93-8. [Medline].
Schachat AP, Maumenee IH. Bardet-Biedl syndrome and related disorders. Arch Ophthalmol. 1982 Feb. 100(2):285-8. [Medline].
Schmidt-Erfurth U. Nutrition and retina. Dev Ophthalmol. 2005. 38:120-47. [Medline].
Schwendemann G, Elze KL, Koepp P, Lagenstein I, Steinhausen HC, Colmant HJ. Juvenile type of generalized ceroid-lipofuscinosis (Spielmeyer-Sjögren syndrome) I. Clinical findings. Neuropadiatrie. 1978 Feb. 9(1):3-27. [Medline].
Shimozawa N, Tsukamoto T, Suzuki Y, et al. A human gene responsible for Zellweger syndrome that affects peroxisome assembly. Science. 1992 Feb 28. 255(5048):1132-4. [Medline].
Small KW, Anderson WB Jr. Pigmented paravenous retinochoroidal atrophy. Discordant expression in monozygotic twins. Arch Ophthalmol. 1991 Oct. 109(10):1408-10. [Medline].
Small KW, Letson R, Scheinman J. Ocular findings in primary hyperoxaluria. Arch Ophthalmol. 1990 Jan. 108(1):89-93. [Medline].
Smith PR, Bain SC, Good PA, et al. Pigmentary retinal dystrophy and the syndrome of maternally inherited diabetes and deafness caused by the mitochondrial DNA 3243 tRNA(Leu) A to G mutation. Ophthalmology. 1999 Jun. 106(6):1101-8. [Medline].
Smith RJ, Lee EC, Kimberling WJ, et al. Localization of two genes for Usher syndrome type I to chromosome 11. Genomics. 1992 Dec. 14(4):995-1002. [Medline].
Stojanovic A, Hwa J. Rhodopsin and retinitis pigmentosa: shedding light on structure and function. Receptors Channels. 2002. 8(1):33-50. [Medline].
Szlyk JP, Fishman GA, Alexander KR, Peachey NS, Derlacki DJ. Clinical subtypes of cone-rod dystrophy. Arch Ophthalmol. 1993 Jun. 111(6):781-8. [Medline].
Szlyk JP, Seiple W, Laderman DJ, Kelsch R, Ho K, McMahon T. Use of bioptic amorphic lenses to expand the visual field in patients with peripheral loss. Optom Vis Sci. 1998 Jul. 75(7):518-24. [Medline].
Takahashi M, Miyoshi H, Verma IM, Gage FH. Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J Virol. 1999 Sep. 73(9):7812-6. [Medline].
Takano Y, Ohguro H, Dezawa M, et al. Study of drug effects of calcium channel blockers on retinal degeneration of rd mouse. Biochem Biophys Res Commun. 2004 Jan 23. 313(4):1015-22. [Medline].
Traboulsi EI, Green WR, Luckenbach MW, de la Cruz ZC. Neuronal ceroid lipofuscinosis. Ocular histopathologic and electron microscopic studies in the late infantile, juvenile, and adult forms. Graefes Arch Clin Exp Ophthalmol. 1987. 225(6):391-402. [Medline].
Travis GH, Brennan MB, Danielson PE, Kozak CA, Sutcliffe JG. Identification of a photoreceptor-specific mRNA encoded by the gene responsible for retinal degeneration slow (rds). Nature. 1989 Mar 2. 338(6210):70-3. [Medline].
Travis GH, Hepler JE. A medley of retinal dystrophies. Nat Genet. 1993 Mar. 3(3):191-2. [Medline].
van Soest S, Westerveld A, de Jong PT, Bleeker-Wagemakers EM, Bergen AA. Retinitis pigmentosa: defined from a molecular point of view. Surv Ophthalmol. 1999 Jan-Feb. 43(4):321-34. [Medline].
Wang DY, Chan WM, Tam PO, et al. Genetic markers for retinitis pigmentosa. Hong Kong Med J. 2005 Aug. 11(4):281-8. [Medline].
Weil D, Blanchard S, Kaplan J, et al. Defective myosin VIIA gene responsible for Usher syndrome type 1B. Nature. 1995 Mar 2. 374(6517):60-1. [Medline].
Weiland JD, Liu W, Humayun MS. Retinal prosthesis. Annu Rev Biomed Eng. 2005. 7:361-401. [Medline].
Weleber RG. Stargardt's macular dystrophy. Arch Ophthalmol. 1994 Jun. 112(6):752-4. [Medline].
Weleber RG, Denman ST, Hanifin JM, Cunningham WJ. Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol. 1986 Jun. 104(6):831-7. [Medline].
Weleber RG, Gregory-Evans K. Retinitis pigmentosa and allied disorders. Ryan SJ. Retina. 4th ed. Philadelphia: Elsevier/Mosby; 2006. Vol I: 395-498.
Wright AF, Jay B, eds. Molecular Genetics of Inherited Eye Disorders. Chur, Switzerland: Harwood; 1994. Vol 2:
Yamazaki H, Ohguro H, Maeda T, et al. Preservation of retinal morphology and functions in royal college surgeons rat by nilvadipine, a Ca(2+) antagonist. Invest Ophthalmol Vis Sci. 2002 Apr. 43(4):919-26. [Medline].
Zeviani M, Moraes CT, DiMauro S, et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology. 1988 Sep. 38(9):1339-46. [Medline].
Zylbermann R, Silverstone BZ, Brandes E, Drukker A. Retinal lesions in Alport's syndrome. J Pediatr Ophthalmol Strabismus. 1980 Jul-Aug. 17(4):255-60. [Medline].